ATE531358T1 - Selbsterhaltende wässrige pharmazeutische zusammensetzungen - Google Patents

Selbsterhaltende wässrige pharmazeutische zusammensetzungen

Info

Publication number
ATE531358T1
ATE531358T1 AT07842914T AT07842914T ATE531358T1 AT E531358 T1 ATE531358 T1 AT E531358T1 AT 07842914 T AT07842914 T AT 07842914T AT 07842914 T AT07842914 T AT 07842914T AT E531358 T1 ATE531358 T1 AT E531358T1
Authority
AT
Austria
Prior art keywords
self
pharmaceutical compositions
aqueous pharmaceutical
supporting aqueous
supporting
Prior art date
Application number
AT07842914T
Other languages
English (en)
Inventor
Bhagwati P Kabra
Masood A Chowhan
L Wayne Schneider
Wesley Wehsin Han
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE531358(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Application granted granted Critical
Publication of ATE531358T1 publication Critical patent/ATE531358T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AT07842914T 2006-09-21 2007-09-20 Selbsterhaltende wässrige pharmazeutische zusammensetzungen ATE531358T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82652906P 2006-09-21 2006-09-21
US82741106P 2006-09-28 2006-09-28
PCT/US2007/079082 WO2008036847A2 (en) 2006-09-21 2007-09-20 Self preserved aqueous pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE531358T1 true ATE531358T1 (de) 2011-11-15

Family

ID=39156274

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07842914T ATE531358T1 (de) 2006-09-21 2007-09-20 Selbsterhaltende wässrige pharmazeutische zusammensetzungen

Country Status (21)

Country Link
US (3) US8268299B2 (de)
EP (1) EP2068822B2 (de)
JP (2) JP4785970B2 (de)
KR (1) KR101021933B1 (de)
AR (1) AR062929A1 (de)
AT (1) ATE531358T1 (de)
AU (1) AU2007299727B2 (de)
BR (1) BRPI0717067A2 (de)
CA (1) CA2606370C (de)
CL (1) CL2007002705A1 (de)
CY (1) CY1112138T1 (de)
DK (1) DK2068822T4 (de)
ES (1) ES2374444T5 (de)
MX (1) MX2009002221A (de)
PL (1) PL2068822T5 (de)
PT (1) PT2068822E (de)
RU (1) RU2436568C2 (de)
SI (1) SI2068822T2 (de)
TW (1) TWI394564B (de)
UY (1) UY30605A1 (de)
WO (1) WO2008036847A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
KR101421519B1 (ko) 2006-09-28 2014-07-30 알콘 리서치, 리미티드 자기 보존 수성 약제학적 조성물
TW200904485A (en) * 2007-05-18 2009-02-01 Alcon Res Ltd Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions
ES2638771T3 (es) * 2008-03-17 2017-10-24 Novartis Ag Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
JP2009256281A (ja) * 2008-04-21 2009-11-05 Teika Seiyaku Kk イソプロピルウノプロストン含有点眼剤組成物
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
AU2009330517A1 (en) * 2008-12-22 2010-07-01 Alcon Research, Ltd. Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
EP2389939A1 (de) 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
TWI618539B (zh) * 2009-12-15 2018-03-21 遠景生物製藥股份有限公司 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
TW201127423A (en) * 2009-12-17 2011-08-16 Alcon Res Ltd Ophthalmic solutions with improved disinfection profiles
KR101946790B1 (ko) 2011-03-04 2019-02-13 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
CA2828635C (en) * 2011-03-04 2020-01-14 Grunenthal Gmbh Parenteral administration of tapentadol
JP6150510B2 (ja) * 2011-12-12 2017-06-21 ロート製薬株式会社 眼科用水性組成物
EP2630952A1 (de) 2012-02-23 2013-08-28 Novagali Pharma S.A. Selbstkonservierende Öldispersionen enthaltend Borsäure
TW201417814A (zh) * 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd 包括瑞巴派特之醫藥組成物
US20150374820A1 (en) * 2013-02-15 2015-12-31 Senju Pharmaceutical Co., Ltd. Difluprednate emulsion composition containing zinc
CN105263476A (zh) 2013-03-13 2016-01-20 库尔制药开发公司 用于治疗炎症的免疫修饰性颗粒
EP3037094A1 (de) 2014-12-23 2016-06-29 Poifa Warszawa SA Ophthalmische pharmazeutische Zusammensetzung
EP3273953B1 (de) 2015-03-27 2019-01-02 Grünenthal GmbH Stabile formulierung zur parenteralen verabreichung von tapentadol
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US10632202B2 (en) 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
CN109996533A (zh) 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
WO2019123266A1 (en) 2017-12-20 2019-06-27 Novartis Ag Ophthalmic composition having a prostaglandin and a beta-blocker
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
WO2021222117A1 (en) 2020-04-27 2021-11-04 Ocular Therapeutix, Inc. Methods of treating allergic conjunctivitis
US20220031739A1 (en) * 2020-07-31 2022-02-03 Eye Therapies Llc Anti-viral compositions and methods of use thereof
EP4393510A4 (de) 2021-09-30 2025-08-06 Rohto Pharma Ophthalmologische zusammensetzung
EP4543456A1 (de) * 2022-06-27 2025-04-30 Zaklady Farmaceutyczne "Polpharma" Spolka Akcyjna Konservierungsmittelfreie ophthalmische zusammensetzung mit einem prostaglandin-analogon
KR20250034105A (ko) 2022-07-06 2025-03-10 로토 세이야쿠 가부시키가이샤 안과 조성물
EP4309644A1 (de) * 2022-07-22 2024-01-24 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Konservierungsfreie ophthalmische zusammensetzung, die ein antiglaukommittel umfasst

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2084870B (en) 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5221664A (en) 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
EP0766970A3 (de) 1990-12-27 2000-02-23 Allergan, Inc Verfahren und Zusammensetzung zum Desinfizieren von Kontaktlinsen
US5460834A (en) 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
CA2132826C (en) * 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5320843A (en) 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
TW274516B (de) 1993-11-12 1996-04-21 Ciba Geigy Ag
AU3070395A (en) 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US6024954A (en) 1994-12-12 2000-02-15 Allergan Compositions and methods for disinfecting contact lenses and preserving contact lens care products
CA2211361A1 (en) 1995-03-20 1996-09-26 Unilever Plc Liquid cleansing formulations
US5683993A (en) 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
HU225329B1 (en) * 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
US6121315A (en) 1996-09-20 2000-09-19 Warner-Lambert Company Oral compositions containing a zinc compound
US5820822A (en) * 1996-10-25 1998-10-13 Kross; Robert D. Antimicrobial composition and method of use
PT948357E (pt) 1996-12-13 2002-10-31 Alcon Lab Inc Utilizacao de amino alcoois de baixo peso molecular em composicoes oftalmicas
US5858346A (en) 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
DK0999825T3 (da) 1997-07-29 2004-02-09 Alcon Lab Inc Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
US6034043A (en) 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6166012A (en) 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
HUP0302161A3 (en) 2000-11-29 2005-01-28 Novartis Ag Aqueous disinfecting systems
AR035509A1 (es) * 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP2004339104A (ja) * 2003-05-14 2004-12-02 Rohto Pharmaceut Co Ltd 溶液の安定化方法
DE602004020665D1 (de) 2003-12-09 2009-05-28 Alcon Inc Verwendung von bisaminen zur verstärkung der antimn
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
WO2005060933A1 (en) 2003-12-11 2005-07-07 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050214382A1 (en) * 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US20070212420A1 (en) 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070297990A1 (en) 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物

Also Published As

Publication number Publication date
DK2068822T3 (da) 2012-01-23
US8323630B2 (en) 2012-12-04
US20110195132A1 (en) 2011-08-11
EP2068822A2 (de) 2009-06-17
BRPI0717067A2 (pt) 2013-09-24
JP2011246476A (ja) 2011-12-08
TW200820962A (en) 2008-05-16
AR062929A1 (es) 2008-12-17
AU2007299727A1 (en) 2008-03-27
DK2068822T4 (da) 2022-10-31
JP2010504358A (ja) 2010-02-12
SI2068822T2 (sl) 2022-10-28
JP5411897B2 (ja) 2014-02-12
EP2068822B2 (de) 2022-07-27
EP2068822B1 (de) 2011-11-02
CL2007002705A1 (es) 2008-05-16
CA2606370C (en) 2012-03-27
SI2068822T1 (sl) 2012-02-29
WO2008036847A3 (en) 2008-05-29
CY1112138T1 (el) 2015-11-04
RU2436568C2 (ru) 2011-12-20
AU2007299727B2 (en) 2011-10-06
UY30605A1 (es) 2008-03-31
PL2068822T5 (pl) 2022-11-14
CA2606370A1 (en) 2008-03-21
ES2374444T3 (es) 2012-02-16
ES2374444T5 (es) 2022-11-21
JP4785970B2 (ja) 2011-10-05
US20130053440A1 (en) 2013-02-28
US8268299B2 (en) 2012-09-18
PT2068822E (pt) 2012-01-10
US20080075790A1 (en) 2008-03-27
KR101021933B1 (ko) 2011-03-16
TWI394564B (zh) 2013-05-01
RU2009114849A (ru) 2010-10-27
KR20090058567A (ko) 2009-06-09
PL2068822T3 (pl) 2012-03-30
WO2008036847A2 (en) 2008-03-27
HK1126667A1 (en) 2009-09-11
AU2007299727A8 (en) 2009-04-09
MX2009002221A (es) 2009-03-13

Similar Documents

Publication Publication Date Title
ATE531358T1 (de) Selbsterhaltende wässrige pharmazeutische zusammensetzungen
EP1992348A4 (de) Pharmazeutische kombination
DK2343071T3 (da) Farmaceutiske doseringsformer
BRPI0715712A2 (pt) Composição farmacêutica
ATE532788T1 (de) Pharmazeutische verbindungen
BRPI0719393A2 (pt) Composição farmacêutica
EP2152237A4 (de) Neue pharmazeutische zusammensetzung
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
EP2124556A4 (de) Pharmazeutische zusammensetzungen
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
ATE493119T1 (de) Pharmazeutische zusammensetzung
DK2068839T3 (da) Farmaceutiske sammensætninger omfattende nilotinib eller salt deraf
NO20075628L (no) Farmasøytiske formuleringer
NO20090578A (no) Farmasøytisk sammensetning inneholdende en tetrahydrofolsyre
RU2398586C3 (ru) Фармацевтическая композиция
EP2025337A4 (de) Topische pharmazeutische zusammensetzung
EP2451274A4 (de) Pharmazeutische zusammensetzungen
EP2419097A4 (de) Pharmazeutische zusammensetzungen
EP2005959A4 (de) Topische pharmazeutische zusammensetzung
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
EP2005958A4 (de) Topische pharmazeutische zusammensetzung
EP2193795A4 (de) Latanoprosthaltige wässrige pharmazeutische zusammensetzung
DK1957073T3 (da) Lægemiddel
BRPI0820198A2 (pt) composições farmacêuticas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2068822

Country of ref document: EP